Evidence map›Paper›PMID 35433959›Full record

ArticleAnnals of translational medicine2022

Overexpression of miR-328-5p influences cell growth and migration to promote NSCLC progression by targeting LOXL4.

Yanzhao Ji, Yanting You, Yifen Wu, Min Wang, Qiuxing He, Xinghong Zhou, Liqian Chen, Xiaomin Sun, Yanyan Liu, Xiuqiong Fu and 4 more

Open access · diamondAbstract read
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Lysyl Oxidase Family Proteins: Prospective Therapeutic Targets in Cancer.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 2 countries.

Yanzhao Ji *Syndrome Laboratory of Integrated of Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, China.
Yanting You *Syndrome Laboratory of Integrated of Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, China.
Yifen Wu *Department of Oncology, Affiliated Dongguan People's Hospital, Southern Medical University, Dongguan, China.
Min WangDepartment of Traditional Chinese Medicine, Zhujiang Hospital of Southern Medical University, Guangzhou, China.
Qiuxing HeSyndrome Laboratory of Integrated of Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, China.
Xinghong ZhouSyndrome Laboratory of Integrated of Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, China.
Liqian ChenSyndrome Laboratory of Integrated of Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, China.
Xiaomin SunSyndrome Laboratory of Integrated of Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, China.
Yanyan LiuSyndrome Laboratory of Integrated of Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, China.
Xiuqiong FuSchool of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
Hiu Yee KwanSchool of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
Qiang ZuoDepartment of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Ren LuoSyndrome Laboratory of Integrated of Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, China.
Xiaoshan ZhaoSyndrome Laboratory of Integrated of Chinese and Western Medicine, School of Chinese Medicine, Southern Medical University, Guangzhou, China.
Southern Medical University · CNHong Kong Baptist University · HKDongguan People’s Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lung cancer is the leading cause of cancer-associated mortality worldwide, and most lung cancers are classified as non-small cell lung cancer (NSCLC). MiR-328 influence the progression of multiple tumors, but the role of miR-328-5p in NSCLC has not been elucidated. The aim of this study was to illuminate the oncogenic role and potential molecular mechanisms of the miR-328-5p and lysyl oxidase like 4 (LOXL4) in NSCLC. Methods: Expression of miR-328-5p was detected by real-time quantitative polymerase chain reaction (qRT-PCR) in tumor and non-tumor adjacent tissues. After Lentivirus-miR-328-5p was employed to intervene this miRNA in NSCLC cell lines, RT-qPCR was used to detect the expression levels of miR-328-5p. Cell Counting Kit-8 (CCK-8), cell colony formation, flow cytometry, wound healing, Transwell assays were used to determine the malignant phenotypes of NSCLC cells. Nude mice models of subcutaneous tumors were established to observe the effect of miR-328-5p on tumorigenesis. Targeting the 3'UTR of LOXL4 by miR-328-5p was verified by integrated analysis including transcriptome sequencing, dual-luciferase and western-blot assays. Results: High miR-328-5p level was observed in NSCLC cells from The Cancer Genome Atlas (TCGA) database and tumor tissues collected from NSCLC patients. Overexpressed miR-328-5p promoted NSCLC cell proliferation, survival, and migration, and promoted tumor growth Conclusions: miR-328-5p showed targeted regulation of LOXL4 to promote cell proliferation and migration in NSCLC.

Indexed as

lysyl oxidase like 4 (LOXL4)miR-328-5pNon-small cell lung cancer (NSCLC)

Identifiers

PMID35433959
PMCPMC9011230
OpenAlexW4224237715

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.